The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
Open accessAbstract
Background and Aims: Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function. Approach and Results: In 216 patients with HCC who were consecutively treated with AtezoBev across 11 tertiary centers, we retrospectively evaluated treatment‐related adverse events (trAEs) graded (G) according to Common Terminology Criteria for Adverse Events v5.0, including in the analysis all patients treated according to label (n = 202, 94%). We also assessed overall survival (OS), progression‐free survival (PFS), overall response (ORR), and disease control rates (DCR) defined by Response Evaluation Criteria in Solid Tumors v1.1. Disease was mostly secondary to viral hepatitis, namely hepatitis C (n = 72; 36%) and hepatitis B infection (n = 35, 17%). Liver function was graded as Child‐Pugh (CP)‐A in 154 patients (76%) and CP‐B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared with CP‐A, patients with CP‐B showed comparable rates of trAEs. Presence and grade of varices at pretreatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow‐up of 9.0 months (95% CI, 7.8–10.1), median OS was 14.9 months (95% CI, 13.6–16.3), whereas median PFS was 6.8 months (95% CI, 5.2–8.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes. Conclusions: This study confirms reproducible safety and efficacy of AtezoBev in routine practice. Patients with CP‐B reported similar tolerability compared with CP‐A, warranting prospective evaluation of AtezoBev in this treatment‐deprived population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Abou-Alfa, G. K., Chan, S. L., Kudo, M., Lau, G., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Dao, T. V., De Toni, E. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.379 · Cited by 388
Self-citation
Cited by
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Self-citationKaplan, D. E., Ripoll, C., Thiele, M., Fortune, B. E., Simonetto, D. A., Garcia-Tsao, G., & Bosch, J. (2024) · Hepatology · doi:10.1097/hep.0000000000000647 · Cited by 486
Ganesan, P., & Kulik, L. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.004 · Cited by 478
Combination immunotherapy for hepatocellular carcinoma
Rimassa, L., Finn, R. S., & Sangro, B. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.003 · Cited by 359
Self-citationSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02745 · Cited by 312
Metadata
- Authors
- D’Alessio, A., Fulgenzi, C. A. M., Nishida, N., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Gaillard, V. E., Saeed, A., Wietharn, B., Hildebrand, H., Wu, L., Ang, C., Marron, T. U., Weinmann, A., Galle, P. R., Bettinger, D., Bengsch, B., Vogel, A., Balcar, L., Scheiner, B., Lee, P., Huang, Y., Amara, S., Muzaffar, M., Naqash, A. R., Cammarota, A., Personeni, N., Pressiani, T., Sharma, R., Pinter, M., Cortellini, A., Kudo, M., Rimassa, L., & Pinato, D. J.
- Venue
- Hepatology
- Published
- 2022-04-08
- Volume
- 76
- Issue
- 4
- Pages
- 1000-1012
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W4220787479
- Cited by
- 235
- References
- 5
- FWCI
- 25.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study. https://app.cochat.ai/papers/10.1002/hep.32468
- The paper
- D’Alessio, A., Fulgenzi, C. A. M., Nishida, N., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Gaillard, V. E., Saeed, A., Wietharn, B., Hildebrand, H., Wu, L., Ang, C., Marron, T. U., Weinmann, A., Galle, P. R., Bettinger, D., Bengsch, B., Vogel, A., . . . Pinato, D. J. (2022). Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study. Hepatology. https://doi.org/10.1002/hep.32468
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.